| Literature DB >> 33591753 |
Yudao Shen1, Fengling Li2, Magdalena M Szewczyk2, Levon Halabelian2, Irene Chau2, Mohammad S Eram2, Carlo Dela Seña2, Kwang-Su Park1, Fanye Meng1, He Chen1, Hong Zeng2, Aiping Dong2, Hong Wu2, Viacheslav V Trush2, David McLeod3, Carlos A Zepeda-Velázquez3, Robert M Campbell4, Mary M Mader4, Brian M Watson4, Matthieu Schapira2, Cheryl H Arrowsmith2,5, Rima Al-Awar3, Dalia Barsyte-Lovejoy2, H Ümit Kaniskan1, Peter J Brown2, Masoud Vedadi2,6, Jian Jin1.
Abstract
Protein arginine methyltransferase 6 (PRMT6) catalyzes monomethylation and asymmetric dimethylation of arginine residues in various proteins, plays important roles in biological processes, and is associated with multiple cancers. To date, a highly selective PRMT6 inhibitor has not been reported. Here we report the discovery and characterization of a first-in-class, highly selective allosteric inhibitor of PRMT6, (R)-2 (SGC6870). (R)-2 is a potent PRMT6 inhibitor (IC50 = 77 ± 6 nM) with outstanding selectivity for PRMT6 over a broad panel of other methyltransferases and nonepigenetic targets. Notably, the crystal structure of the PRMT6-(R)-2 complex and kinetic studies revealed (R)-2 binds a unique, induced allosteric pocket. Additionally, (R)-2 engages PRMT6 and potently inhibits its methyltransferase activity in cells. Moreover, (R)-2's enantiomer, (S)-2 (SGC6870N), is inactive against PRMT6 and can be utilized as a negative control. Collectively, (R)-2 is a well-characterized PRMT6 chemical probe and a valuable tool for further investigating PRMT6 functions in health and disease.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33591753 PMCID: PMC8035306 DOI: 10.1021/acs.jmedchem.0c02160
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446